D. Boral Capital lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $2 from $3 and keeps a Buy rating on the shares. The firm cites dilution from the capital raise for the target cut.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX: